🇺🇸

M&A Activity

· daily

US Merger & Acquisition SEC Filings — March 11, 2026

The 9 filings reveal a vibrant SPAC-driven M&A landscape, with 6/9 involving SPACs at various stages: IPO consummation (GalaxyEdge $100M), shareholder approvals (TLGY 97% vote, 6.7% redemptions), extensions (Future Vision II to April 13), clarifications (Pelican no 1% excise tax), terminations (Yotta), and underwriting amendments (Quantumsphere/Quartzsea at 4% deferred commissions). Sonida Senior Living's $1.8B merger completion with CNL Healthcare stands out, delivering 62% Normalized FFO accretion, 153 communities, and $930M debt financing for a $3.3B entity. Joby's $30.75M property loan supports eVTOL expansion. No explicit YoY/QoQ financial trends reported, but low TLGY redemptions (6.7% vs typical 20-50% in SPACs) and Sonida's 50/50 ownership split signal strong deal momentum. Portfolio-level patterns show 4 positive, 1 negative, 4 neutral sentiments; active capital raises/extensions indicate persistent M&A pursuit despite headwinds. Implications: heightened takeover activity favors operators like Sonida, while SPACs offer merger catalysts.

9 high priority 9 total filings
· daily

US Merger & Acquisition SEC Filings — March 10, 2026

The 12 filings highlight intense SPAC activity (7/12 filings) focused on lifecycle management including over-allotments, trust extensions, unit separations, and de-SPAC progress, signaling sustained M&A pursuit amid avoiding liquidations. Ashford Hospitality's $95.3M hotel sale enabled $94.7M debt reduction, improving pro forma equity deficit by 15% to $453M from $533M (as of Sep 30, 2025), though 2024 revenue dipped 2% YoY to $1.15B with mixed net loss trends (94% improvement in 2024 to $5.3M but slight 9M2025 worsening to $137.6M). Governance shifts and dilutions dominate non-SPAC filings, with Klotho authorizing 50k Series C preferred convertible to 2.13B common shares post-approval, and Strategic Acquisitions issuing 40M shares boosting insider ownership to 86% via dilution. Forward-looking catalysts include SPAC combination deadlines (e.g., byNordic to Apr 12, 2026) and merger filings (Lake Superior F-4 upcoming), while Eventbrite's share authorization slash to 100 signals imminent going-private or merger. No broad portfolio revenue growth (only Ashford data shows -2% YoY), but capital allocation leans to debt reduction and extensions; neutral/mixed sentiment prevails (9/12), with SPACs showing positive procedural wins. Implications: M&A pipelines active but dilution risks high for microcaps, favoring selective SPAC plays with extensions.

12 high priority 12 total filings
· daily

US Merger & Acquisition SEC Filings — March 09, 2026

The 14 filings reveal a surge in US M&A and SPAC activity on March 9, 2026, with 10 SPAC-related events dominating (mergers, extensions, IPO upsizes), signaling robust blank-check dealmaking amid energy, AI, and defense sectors. Key completions include Presidio Production's business combination with $87.5M PIPE and $125M preferred, CACI's $2.6B ARKA acquisition enhancing EO/IR capabilities, and MiniMed's $538M IPO proceeds post-Medtronic spin-off. Positive sentiment prevails in 11/14 filings (79%), with total announced/closed deal values exceeding $3.5B (CACI $2.6B, Calisa $180M, Presidio $212.5M PIPE+pref, MiniMed $538M). No broad period-over-period financial declines noted, but SPAC extensions (Aquaron $16K note, Ribbon $600K note) indicate deadline pressures without redemptions flagged. Mixed promo in Pelican/Greenland adds hype to energy exploration, while Trailblazer's Nasdaq non-compliance poses isolated delisting risk. Portfolio trend: SPAC de-SPACs accelerating (3 announced/closed vs prior briefs), favoring liquidity events and sector rotation into geothermal/AI/oil.

14 high priority 14 total filings
· daily

US Merger & Acquisition SEC Filings — March 06, 2026

The 12 filings reveal a surge in SPAC lifecycle events (7/12 filings), including IPOs raising $572M+ in trust proceeds (APEX $112M, Illumination $230M), non-redemption agreements to extend deadlines (Crown PropTech to March 2027), and promissory notes for operations (Artius II up to $1M), signaling robust M&A pipeline activity amid tight timelines. Completed M&A/divestitures dominate the rest (4/12), with accretive buys like Chatham Lodging's $92M hotel acquisition (RevPAR $116 vs prior sold $101, margins 42% vs 27%, +12% EBITDA) and Kratos' $353M Orbit deal, plus Albemarle's $670M asset sales for debt reduction; High Wire's $150k settlement clears $804k liabilities to enable takeover. Governance crises in Drugs Made In America entities (3 filings) highlight sponsor irregularities ($1.1M improper withdrawals post-IPO, no trust impact but CEO removals), contrasting positive sentiment (9/12 positive/neutral). No broad YoY/QoQ revenue trends due to transactional nature, but capital allocation leans toward accretive M&A/debt paydown vs dividends (Chatham +11% to $0.10/share). Portfolio-level: SPACs preserve ~$1B+ in trusts for deals; M&A valuations attractive ($156k/room Chatham, $13.73/share Orbit). Implications: Heightened M&A catalysts Q1-Q2 2026, watch SPAC redemptions and Drugs resolutions for volatility.

12 high priority 12 total filings
· daily

US Merger & Acquisition SEC Filings — March 05, 2026

The USA M&A & Takeover Activity stream reveals a surge in SPAC activity with 8 out of 12 filings tied to blank check companies, including IPOs raising over $1.1B collectively (Averin $284M, Fortress $250M, TRG $200M, Kensington $200M, GalaxyEdge $100M), extensions (Athena), and unit separations (OneIM), signaling robust dealflow targeting tech, AI, quantum, LatAm, automotive/defense/energy. Actual M&A highlights include Pasqal's $2B SPAC merger with Bleichroeder offering $600M proceeds amid 100% 2025 revenue growth, and T Stamp's acquisition of Lexverify for LLM expertise. Camp4 Therapeutics reported mixed FY2025 results with revenue exploding 437% YoY to $3.5M and cash runway to 2028, but net loss widened 55% YoY to $80.4M due to non-cash charges. Period-over-period trends show strong fundraising momentum but pockets of financial strain like Fortress's $13.2M shareholders' deficit post-IPO and Invest's material weaknesses in controls. Portfolio-level patterns indicate heightened M&A appetite in quantum computing, biotech, and AI, with H2 2026 catalysts from closings and trials; implications favor long SPAC proxies and targets ahead of redemptions.

12 high priority 12 total filings
· daily

US Merger & Acquisition SEC Filings — March 04, 2026

Across 11 US SEC filings on March 3-4, 2026, M&A and takeover activity surges with 5 SPAC-related updates (mergers advancing, IPOs, PFIC statements), 3 major acquisitions ($2.7B CMCO, $450k Invech, Ventyx change-in-control), and 3 divestitures ($50.1M SITE, snacks HAIN, $210M CMCO) focused on debt reduction and portfolio sharpening. Positive sentiment prevails in 5/11 filings (45%), neutral in 5, signaling strategic execution amid no broad period-over-period declines reported; pro forma data in CMCO reflects post-deal leverage without synergies quantified. Key themes: SPAC de-risking via warrant exchanges/support (Haymaker 49.8% holders), debt-financed growth (CMCO $3.35B facilities), and non-core asset sales boosting liquidity (HAIN focuses on higher-margin yogurt/tea). Market implications include M&A arbitrage potential in SPACs, deleveraging tailwinds for consumer/industrials, and watch for dilution from convertibles/preferreds. No insider trading or explicit YoY/QoQ trends across filings, but forward-looking catalysts like warrant meetings and note maturities loom. Portfolio-level pattern: 7/11 filings advance deals without red flags on metrics, favoring tactical longs in completers.

11 high priority 11 total filings
· daily

US Merger & Acquisition SEC Filings — March 03, 2026

The 7 filings reveal a vibrant USA M&A and takeover landscape dominated by SPAC activity (4/7 filings), with two fresh IPOs raising $225M combined ($100M APEX, $125M Clearthink), one extension to March 2027 with near-zero redemptions (Piermont), and operational funding via $1.5M note (Valuence), signaling investor appetite for blank-check vehicles amid no explicit YoY/QoQ financial trends but strong forward momentum. Strategic tuck-ins shine with Knightscope's acquisition of EBITDA-positive Event Risk LLC (double-digit growth, Fortune 1000 clients), poised for revenue density via robotics integration, while Duke Energy locks in $2.8B initial minority stake from Brookfield (phased to $6B total by 2028, 19.7% ownership). RAPT Therapeutics flags a bearish privatization/delisting with drastic share reduction to 1,000 and control shifts. Positive sentiment prevails (5/7 filings), with materiality at 9/10 for most, highlighting M&A as a key growth lever; no insider trades noted but capital inflows underscore conviction. Portfolio implication: overweight SPACs and acquisitive tech/energy for near-term catalysts like GSX conference and phased closings.

7 high priority 7 total filings
· daily

US Merger & Acquisition SEC Filings — March 02, 2026

A surge in US M&A and takeover activity dominates the 29 filings from March 2, 2026, with 12 completed mergers/acquisitions (primarily banking consolidations adding $20B+ in combined assets) and robust SPAC developments including 4 IPOs raising $800M+, 3 extensions, and 2 business combination approvals/proxies. Banking sector leads with 7 deals (e.g., HBT Financial +$1.8B assets, Farmers National +42% to $7.4B), driving footprint expansions in Midwest/East Coast without reported declines. Positive sentiment prevails in 17/29 filings (avg materiality 8.7/10), bolstered by accretive deals (e.g., Malibu Boats 7.2x EBITDA, Crexendo to $100M run-rate), though mixed signals in energy (Kosmos Q4 loss $377M despite +4% QoQ production). SPACs show high activity but delays/extensions flag execution risks. Forward-looking catalysts cluster in Q1 2026 (closings, earnings), with no insider trading disclosed but board additions signaling integration confidence. Portfolio trend: Asset growth avg +30% in banks vs sector contraction risks elsewhere; implications favor M&A arbitrage and regional bank longs amid consolidation wave.

29 high priority 29 total filings
· daily

US Merger & Acquisition SEC Filings — February 27, 2026

A surge in SPAC activity dominates the 9 filings from February 27, 2026, with 3 new SPAC IPOs raising a combined $586M ($125M Clearthink, $261M MOZAYYX upsized, $200M TRG Latin America), signaling robust investor appetite for blank-check companies targeting financial services, general M&A, and Latin America. De-SPAC progress is evident in Real Asset Acquisition Corp.'s definitive agreement with IQM Finland for quantum computing (potential Nasdaq listing) and Voyager Acquisition Corp.'s merger approval with VERAXA Biotech (Nasdaq: VRXA post-close). Avidity Biosciences reports a completed takeover with change of control, delisting, and agreement termination, marking a rare public-to-private shift. Vague filings from Abony, Roman DBDR, and Miluna highlight undisclosed M&A or governance events amid neutral sentiment. No period-over-period financial trends available across filings, but transaction volumes indicate heightened M&A momentum in tech/biotech/SPACs versus subdued traditional M&A. Capital allocation absent; forward-looking catalysts include IPO closings Feb 25-27, 2026, and conference calls. Implications: SPAC IPO boom offers entry points for merger arbitrage, while delisting/takeover in Avidity flags liquidity risks.

9 high priority 9 total filings